{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:00:48Z","timestamp":1790265648172,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Nirmatrelvir (coadministered with ritonavir as PAXLOVID<jats:sup>TM<\/jats:sup>) reduces the risk of COVID-19-related hospitalizations and all-cause death in individuals with mild-to-moderate COVID-19 at high risk of progression to severe disease. Ritonavir is coadministered as a pharmacokinetic enhancer. However, ritonavir may cause drug-drug interactions (DDIs) due to its interactions with various drug-metabolizing enzymes and transporters, including cytochrome P450 (CYP) 3A, CYP2D6, and P-glycoprotein transporters. To better understand the extent of DDIs (or lack thereof) of nirmatrelvir; ritonavir in a clinical setting, this study used real-world evidence (RWE) from the Optum Clinformatics Data Mart database to identify the top 100 drugs most commonly prescribed to US patients at high risk of progression to severe COVID-19 disease. The top 100 drugs were identified based on total counts associated with drugs prescribed to high-risk patients (i.e., \u2009\u2265\u20091 medical condition associated with an increased risk of severe COVID-19) who were continuously enrolled in the database throughout 2019 and had \u2009\u2265\u20091 prescription claim. Each of the 100 drugs was then assessed for DDI risk based on their metabolism, excretion, and transport pathways identified from available US prescribing and medical literature sources. Seventy drugs identified were not expected to have DDIs with nirmatrelvir; ritonavir, including many cardiovascular agents, anti-infectives, antidiabetic agents, and antidepressants. Conversely, 30 drugs, including corticosteroids, narcotic analgesics, anticoagulants, statins, and sedatives\/hypnotics, were expected to cause DDIs with nirmatrelvir; ritonavir. This RWE analysis is complementary to the prescribing information and other DDI management tools for guiding healthcare providers in managing DDIs.<\/jats:p>\n                <jats:p><jats:bold>Graphical Abstract<\/jats:bold><\/jats:p>","DOI":"10.1208\/s12248-023-00832-3","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T02:03:16Z","timestamp":1689818596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Real-World Evidence of the Top 100 Prescribed Drugs in the USA and Their Potential for Drug Interactions with Nirmatrelvir; Ritonavir"],"prefix":"10.1208","volume":"25","author":[{"given":"Jacqueline","family":"Gerhart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florin","family":"Draica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Benigno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Reimbaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenick","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Baillon-Plot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurinder Singh","family":"Sidhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharat D.","family":"Damle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"832_CR1","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1126\/science.abl4784","volume":"374","author":"DR Owen","year":"2021","unstructured":"Owen DR, Allerton CMN, Anderson AS, Aschenbrenner L, Avery M, Berritt S, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374:1586\u201393.","journal-title":"Science"},{"key":"832_CR2","unstructured":"US Food and Drug Administration. Fact sheet for healthcare providers: emergency use authorization for PAXLOVIDTM. Available at: https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=16474. Accessed 6 Dec 2022."},{"key":"832_CR3","doi-asserted-by":"crossref","unstructured":"Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W, et al. Effect of nirmatrelvir\/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. Presented at: IDWeek 2022, October 19-23, 2022; Washington, DC, USA.","DOI":"10.1093\/ofid\/ofac492.047"},{"key":"832_CR4","unstructured":"National Institutes of Health. Coronavirus disease 2019 (COVID-19) treatment guidelines. Available at: https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed 8 Aug 2022."},{"key":"832_CR5","doi-asserted-by":"publisher","first-page":"18422","DOI":"10.1073\/pnas.1010693107","volume":"107","author":"IF Sevrioukova","year":"2010","unstructured":"Sevrioukova IF, Poulos TL. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci U S A. 2010;107:18422\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"832_CR6","unstructured":"Norvir (ritonavir). Full Prescribing Information, AbbVie, North Chicago, IL, 2017."},{"key":"832_CR7","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1097\/00002030-199909100-00004","volume":"13","author":"L Profit","year":"1999","unstructured":"Profit L, Eagling VA, Back DJ. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS. 1999;13:1623\u20137.","journal-title":"AIDS"},{"key":"832_CR8","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02404-21","volume":"66","author":"RL Atmar","year":"2022","unstructured":"Atmar RL, Finch N. New perspectives on antimicrobial agents: molnupiravir and nirmatrelvir\/ritonavir for treatment of COVID-19. Antimicrob Agents Chemother. 2022;66: e0240421.","journal-title":"Antimicrob Agents Chemother"},{"key":"832_CR9","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1124\/dmd.106.009290","volume":"34","author":"M Hirano","year":"2006","unstructured":"Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34:1229\u201336.","journal-title":"Drug Metab Dispos"},{"key":"832_CR10","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1002\/jps.23477","volume":"102","author":"Y Shitara","year":"2013","unstructured":"Shitara Y, Takeuchi K, Horie T. Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. J Pharm Sci. 2013;102:3427\u201335.","journal-title":"J Pharm Sci"},{"key":"832_CR11","doi-asserted-by":"crossref","unstructured":"Cox DS, Rehman M, Khan T, Ginman K, Salageanu J, LaBadie RR, et al. Effects of nirmatrelvir\/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants. Br J Clin Pharmacol. 2023. Accepted - in press.","DOI":"10.1111\/bcp.15835"},{"key":"832_CR12","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.2011.164","volume":"90","author":"S Katzenmaier","year":"2011","unstructured":"Katzenmaier S, Markert C, Riedel KD, Burhenne J, Haefeli WE, Mikus G. Determining the time course of CYP3A inhibition by potent reversible and irreversible CYP3A inhibitors using a limited sampling strategy. Clin Pharmacol Ther. 2011;90:666\u201373.","journal-title":"Clin Pharmacol Ther"},{"key":"832_CR13","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1002\/cpt.2646","volume":"112","author":"C Marzolini","year":"2022","unstructured":"Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, et al. Recommendations for the management of drug-drug interactions between the COVID-19 antiviral nirmatrelvir\/ritonavir (Paxlovid) and comedications. Clin Pharmacol Ther. 2022;112:1191\u2013200.","journal-title":"Clin Pharmacol Ther"},{"key":"832_CR14","doi-asserted-by":"publisher","first-page":"3084","DOI":"10.1093\/jac\/dkaa253","volume":"75","author":"F Stader","year":"2020","unstructured":"Stader F, Khoo S, Stoeckle M, Back D, Hirsch HH, Battegay M, et al. Stopping lopinavir\/ritonavir in COVID-19 patients: duration of the drug interacting effect. J Antimicrob Chemother. 2020;75:3084\u20136.","journal-title":"J Antimicrob Chemother"},{"key":"832_CR15","doi-asserted-by":"crossref","unstructured":"Cox DS, Van Eyck L, Pawlak S, Beckerman B, Linn C, Ginman K, et al. Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir\/ritonavir in healthy adults. Br J Clin Pharmacol. 2023. Online ahead of print.","DOI":"10.1111\/bcp.15788"},{"key":"832_CR16","first-page":"37","volume":"17","author":"B Renjifo","year":"2015","unstructured":"Renjifo B, van Wyk J, Salem AH, Bow D, Ng J, Norton M. Pharmacokinetic enhancement in HIV antiretroviral therapy: a comparison of ritonavir and cobicistat. AIDS Rev. 2015;17:37\u201346.","journal-title":"AIDS Rev"},{"key":"832_CR17","unstructured":"National Institutes of Health. Drug-drug interactions between ritonavir-boosted nirmatrelvir (Paxlovid) and concomitant medications. Available at: https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/antiviral-therapy\/ritonavir-boosted-nirmatrelvir--paxlovid-\/paxlovid-drug-drug-interactions\/. Accessed 9 Oct 2022."},{"key":"832_CR18","unstructured":"Ontario COVID-19 Drugs and Biologics Clinical Practice Guidelines Working Group; University of Waterloo School of Pharmacy. Nirmatrelvir\/ritonavir (Paxlovid): What prescribers and pharmacists need to know. Available at: https:\/\/covid19-sciencetable.ca\/sciencebrief\/nirmatrelvir-ritonavir-paxlovid-what-prescribers-and-pharmacists-need-to-know-3-0\/. Accessed 8 Aug 2022."},{"key":"832_CR19","unstructured":"University of Liverpool. COVID-19 drug interaction. Available at: https:\/\/www.covid19-druginteractions.org\/checker. Accessed 9 Oct 2022."},{"key":"832_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.therap.2022.03.005","volume":"77","author":"F Lemaitre","year":"2022","unstructured":"Lemaitre F, Gr\u00e9goire M, Monchaud C, Bouchet S, Saint-Salvi B, Polard E. Management of drug-drug interactions with nirmatrelvir\/ritonavir in patients treated for Covid-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT). Therapie. 2022;77:509\u201321.","journal-title":"Therapie"},{"key":"832_CR21","doi-asserted-by":"crossref","unstructured":"Lemaitre F, Budde K, Van Gelder T, Bergan S, Lawson R, Noceti O, et al. Therapeutic drug monitoring and dosage adjustments of immunosuppressive drugs when combined with nirmatrelvir\/ritonavir in patients with COVID-19. Ther Drug Monit. 2022;45:191\u20139.","DOI":"10.1097\/FTD.0000000000001014"},{"key":"832_CR22","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1007\/s00228-022-03370-7","volume":"78","author":"N Yalcin","year":"2022","unstructured":"Yalcin N, Allegaert K. COVID-19 and antiepileptic drugs: an approach to guide practices when nirmatrelvir\/ritonavir is co-prescribed. Eur J Clin Pharmacol. 2022;78:1697\u2013701.","journal-title":"Eur J Clin Pharmacol"},{"key":"832_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102451","volume":"16","author":"SK Shini Rubina","year":"2022","unstructured":"Shini Rubina SK, Anuba PA, Swetha B, Kalala KP, Pm A, Sabarathinam S. Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: an evidence-based review from six databases. Diabetes Metab Syndr. 2022;16: 102451.","journal-title":"Diabetes Metab Syndr"},{"key":"832_CR24","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ijid.2022.06.059","volume":"122","author":"CS Larsen","year":"2022","unstructured":"Larsen CS. Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19. Int J Infect Dis. 2022;122:599\u2013601.","journal-title":"Int J Infect Dis"},{"key":"832_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1093\/cid\/ciac180","volume":"76","author":"LD Saravolatz","year":"2023","unstructured":"Saravolatz LD, Depcinski S, Sharma M. Molnupiravir and nirmatrelvir-ritonavir: oral coronavirus disease 2019 antiviral drugs. Clin Infect Dis. 2023;76:165\u201371.","journal-title":"Clin Infect Dis"},{"key":"832_CR26","first-page":"263","volume":"119","author":"G Mikus","year":"2022","unstructured":"Mikus G, Foerster KI, Terstegen T, Vogt C, Said A, Schulz M, et al. Oral drugs against COVID-19. Dtsch Arztebl Int. 2022;119:263\u20139.","journal-title":"Dtsch Arztebl Int"},{"key":"832_CR27","unstructured":"Centers for Disease Control and Prevention. People with certain medical conditions. December 6, 2022. Available at: https:\/\/www.cdc.gov\/coronavirus\/2019-ncov\/need-extra-precautions\/people-with-medical-conditions.html. Accessed 11 Jan 2023."},{"key":"832_CR28","unstructured":"Vfend (voriconazole). Full Prescribing Information, Pfizer Inc, New York, NY, 2010."},{"key":"832_CR29","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.clpt.2005.09.001","volume":"78","author":"RE Aarnoutse","year":"2005","unstructured":"Aarnoutse RE, Kleinnijenhuis J, Koopmans PP, Touw DJ, Wieling J, Hekster YA, et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin Pharmacol Ther. 2005;78:664\u201374.","journal-title":"Clin Pharmacol Ther"},{"key":"832_CR30","unstructured":"Zithromax (azithromycin). Full Prescribing Information, Pfizer Labs, New York, NY, 2021."},{"key":"832_CR31","unstructured":"Prinivil (lisinopril). Full Prescribing Information, Merck & Co., Inc., Whitehouse Station, NJ, 2021."},{"key":"832_CR32","unstructured":"Riomet (metformin hydrochloride). Full Prescribing Information, Sun Pharmaceuticals, Cranbury, NJ, 2018."},{"key":"832_CR33","unstructured":"Albuterol sulfate (albuterol sulfate inhalation solution). Full Prescribing Information, Mylan Pharmaceuticals, Morgantown, WV, 2021."},{"key":"832_CR34","unstructured":"Centany (mupirocin). Full Prescribing Information, Medimetriks Pharmaceuticals, Fairfield, NJ, 2015."},{"key":"832_CR35","unstructured":"Zocor (simvastatin). Full Prescribing Information, Oragon LLC, Jersey City, NJ, 2023."},{"key":"832_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0009-9236(98)90130-8","volume":"64","author":"JJ Lilja","year":"1998","unstructured":"Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther. 1998;64:477\u201383.","journal-title":"Clin Pharmacol Ther"},{"key":"832_CR37","unstructured":"US Food and Drug Administration. FDA updates on Paxlovid for health care providers. Available at: https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-updates-paxlovid-health-care-providers. Accessed 18 Nov 2022."},{"key":"832_CR38","doi-asserted-by":"publisher","first-page":"412","DOI":"10.7861\/clinmedicine.16-5-412","volume":"16","author":"ER Elliot","year":"2016","unstructured":"Elliot ER, Theodoraki A, Jain LR, Marshall NJ, Boffito M, Baldeweg SE, et al. Iatrogenic Cushing\u2019s syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies. Clin Med (Lond). 2016;16:412\u20138.","journal-title":"Clin Med (Lond)"},{"key":"832_CR39","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/JPR.S138698","volume":"10","author":"XQ Feng","year":"2017","unstructured":"Feng XQ, Zhu LL, Zhou Q. Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management. J Pain Res. 2017;10:1225\u201339.","journal-title":"J Pain Res"},{"key":"832_CR40","first-page":"S51","volume":"8","author":"L Fala","year":"2015","unstructured":"Fala L, Welz JA. New perspectives in the treatment of opioid-induced respiratory depression. Am Health Drug Benefits. 2015;8:S51-63.","journal-title":"Am Health Drug Benefits"},{"key":"832_CR41","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/phar.2397","volume":"40","author":"S Dashti-Khavidaki","year":"2020","unstructured":"Dashti-Khavidaki S, Khalili H. Considerations for statin therapy in patients with COVID-19 [Letter]. Pharmacotherapy. 2020;40:484\u20136.","journal-title":"Pharmacotherapy"},{"key":"832_CR42","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/cpt.1099","volume":"105","author":"MK Itkonen","year":"2019","unstructured":"Itkonen MK, Tornio A, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, et al. Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel. Clin Pharmacol Ther. 2019;105:219\u201328.","journal-title":"Clin Pharmacol Ther"},{"key":"832_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1007\/s11239-015-1310-7","volume":"41","author":"AE Burnett","year":"2016","unstructured":"Burnett AE, Mahan CE, Vazquez SR, Oertel LB, Garcia DA, Ansell J. Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis. 2016;41:206\u201332.","journal-title":"J Thromb Thrombolysis"},{"key":"832_CR44","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1182\/blood-2018-06-848747","volume":"132","author":"SR Vazquez","year":"2018","unstructured":"Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions. Blood. 2018;132:2230\u20139.","journal-title":"Blood"},{"key":"832_CR45","doi-asserted-by":"crossref","unstructured":"Cacabelos R, Cacabelos P, Torrellas C. Chapter 27 - Personalized medicine of Alzheimer\u2019s disease. In: Padmanabhan S, editor. Handbook of Pharmacogenomics and Stratified Medicine. San Diego: Academic Press; 2014. p. 563\u2013615.","DOI":"10.1016\/B978-0-12-386882-4.00027-X"},{"key":"832_CR46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4137\/DTI.S12519","volume":"7","author":"ML Amin","year":"2013","unstructured":"Amin ML. P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights. 2013;7:27\u201334.","journal-title":"Drug Target Insights"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-023-00832-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-023-00832-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-023-00832-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T19:02:35Z","timestamp":1695409355000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-023-00832-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["832"],"URL":"https:\/\/doi.org\/10.1208\/s12248-023-00832-3","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"17 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are employees of and may hold stock or options in Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"73"}}